London, UK - November 19th - November 21st, 2023, evidence-based data from the VitaFlow® Transcatheter Aortic Valve (VitaFlow®), developed by MicroPort® CardioFlow (hereinafter referred to as MicroPort® CardioFlow, stock code: 02160.HK), were revealed on PCR London Valves, a leading global event on structural heart diseases. The data showed that the long-term and excellent clinical outcomes of VitaFlow® have reached the international mainstream level, and this is also the first time for the domestically-developed transcatheter aortic valve system to publish 7-year long-term follow-up data in the international authoritative academic arena in the field of interventional treatment of heart valve disease.